The University of Chicago Header Logo

Connection

Fredric L. Coe to Crystallization

This is a "connection" page, showing publications Fredric L. Coe has written about Crystallization.
Connection Strength

1.595
  1. Evidence for disordered acid-base handling in calcium stone-forming patients. Am J Physiol Renal Physiol. 2020 02 01; 318(2):F363-F374.
    View in: PubMed
    Score: 0.173
  2. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol. 2011 Aug; 6(8):2083-92.
    View in: PubMed
    Score: 0.097
  3. Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res. 2010 Dec; 38(6):439-52.
    View in: PubMed
    Score: 0.092
  4. Medicine. Stopping the stones. Science. 2010 Oct 15; 330(6002):325-6.
    View in: PubMed
    Score: 0.092
  5. Pathophysiological correlates of two unique renal tubule lesions in rats with intestinal resection. Am J Physiol Renal Physiol. 2006 Nov; 291(5):F1061-9.
    View in: PubMed
    Score: 0.070
  6. Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers. Am J Physiol Renal Physiol. 2006 Sep; 291(3):F530-6.
    View in: PubMed
    Score: 0.067
  7. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol. 2002 Jun; 167(6):2372-6.
    View in: PubMed
    Score: 0.051
  8. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int. 2002 May; 61(5):1821-9.
    View in: PubMed
    Score: 0.051
  9. Does a failure of crystal inhibition cause calcium renal stones? Nephron. 2002 Apr; 90(4):361-4.
    View in: PubMed
    Score: 0.051
  10. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol. 2001 Aug; 166(2):688-93.
    View in: PubMed
    Score: 0.048
  11. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int. 1999 Oct; 56(4):1505-16.
    View in: PubMed
    Score: 0.043
  12. Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol. 1999 Apr; 161(4):1077-81.
    View in: PubMed
    Score: 0.041
  13. Foscarnet crystal deposition and renal failure. Am J Kidney Dis. 1998 Sep; 32(3):519-20.
    View in: PubMed
    Score: 0.040
  14. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol. 1998 08; 275(2):F255-61.
    View in: PubMed
    Score: 0.039
  15. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol. 1998 Jun; 159(6):1821-5.
    View in: PubMed
    Score: 0.039
  16. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int. 1997 Dec; 52(6):1602-8.
    View in: PubMed
    Score: 0.038
  17. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int. 1997 Mar; 51(3):640-5.
    View in: PubMed
    Score: 0.036
  18. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 1997 Mar; 51(3):894-900.
    View in: PubMed
    Score: 0.036
  19. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016 Dec; 29(6):715-734.
    View in: PubMed
    Score: 0.034
  20. Normal calcium oxalate crystal growth inhibition in severe calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1996 Apr; 7(4):602-7.
    View in: PubMed
    Score: 0.033
  21. Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol. 1996 Apr; 270(4 Pt 2):F604-13.
    View in: PubMed
    Score: 0.033
  22. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab. 1994; 20(6):378-84.
    View in: PubMed
    Score: 0.029
  23. Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int. 2012 Jun; 81(11):1140-8.
    View in: PubMed
    Score: 0.025
  24. Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol. 1991 Nov; 261(5 Pt 2):F824-30.
    View in: PubMed
    Score: 0.025
  25. Inhibitors within the nephron. Am J Kidney Dis. 1991 Apr; 17(4):407-13.
    View in: PubMed
    Score: 0.024
  26. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol. 1991 Apr; 260(4 Pt 2):F569-78.
    View in: PubMed
    Score: 0.024
  27. Isolation of nephrocalcin from kidney tissue of nine vertebrate species. Am J Physiol. 1991 Feb; 260(2 Pt 2):F243-8.
    View in: PubMed
    Score: 0.023
  28. Defenses of an unstable compromise: crystallization inhibitors and the kidney's role in mineral regulation. Kidney Int. 1990 Oct; 38(4):625-31.
    View in: PubMed
    Score: 0.023
  29. Evidence that mouse renal proximal tubule cells produce nephrocalcin. Am J Physiol. 1989 Sep; 257(3 Pt 2):F390-8.
    View in: PubMed
    Score: 0.021
  30. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol. 1989 Jul; 257(1 Pt 2):F99-106.
    View in: PubMed
    Score: 0.021
  31. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat Rec (Hoboken). 2008 Mar; 291(3):325-34.
    View in: PubMed
    Score: 0.019
  32. Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int. 2007 Dec; 72(12):1503-11.
    View in: PubMed
    Score: 0.019
  33. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest. 1987 Jun; 79(6):1782-7.
    View in: PubMed
    Score: 0.018
  34. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 2006 Jun; 69(12):2227-35.
    View in: PubMed
    Score: 0.017
  35. Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest. 1985 Oct; 76(4):1455-62.
    View in: PubMed
    Score: 0.016
  36. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 2005 Feb; 67(2):576-91.
    View in: PubMed
    Score: 0.015
  37. Hyperuricosuria and calcium nephrolithiasis. Urol Clin North Am. 1981 Jun; 8(2):227-44.
    View in: PubMed
    Score: 0.012
  38. Clinical characteristics and pathogenetic mechanisms in hyperuricosuric calcium oxalate renal stone disease. Scand J Urol Nephrol Suppl. 1980; 53:171-7.
    View in: PubMed
    Score: 0.011
  39. Isolation and characterization of calcium oxalate crystal growth inhibitors from human urine. Biochem Biophys Res Commun. 1978 Oct 30; 84(4):1038-44.
    View in: PubMed
    Score: 0.010
  40. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int. 1978 May; 13(5):418-26.
    View in: PubMed
    Score: 0.010
  41. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998 Jan; 53(1):194-9.
    View in: PubMed
    Score: 0.009
  42. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med. 1975 Sep; 149(4):926-9.
    View in: PubMed
    Score: 0.008
  43. A new spectrophotometric method for measuring calcium oxalate monohydrate crystal aggregation in the absence of supersaturation: inhibitory effects of urinary glycoproteins. Urol Res. 1989; 17(3):149-50.
    View in: PubMed
    Score: 0.005
  44. Molecular abnormality of urinary glycoprotein crystal growth inhibitor in calcium nephrolithiasis. Trans Assoc Am Physicians. 1985; 98:281-9.
    View in: PubMed
    Score: 0.004
  45. Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem. 1983 Oct 25; 258(20):12594-600.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.